The BioPharm Brief: Breakthrough Biologics and Long-Term Wins in IBD and Beyond

May 05, 05:18 PM
Headliner
Share
Subscribe

Phase III data in thyroid eye disease, long-term ulcerative colitis outcomes, and Crohn disease advances highlight continued momentum in biologics and immunology innovation.

Share
Subscribe
Next
The BioPharm Brief: Precision, Immunotherapy, Expansion
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief